Clinical Trial Detail

NCT ID NCT02922764
Title A Study of RGX-104 With or Without Nivolumab in Patients With Advanced Solid Malignancies and Lymphoma
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements yes
Sponsors Rgenix, Inc.
Indications

lymphoma

ovary epithelial cancer

peritoneum cancer

fallopian tube cancer

Advanced Solid Tumor

lung small cell carcinoma

urinary bladder cancer

melanoma

non-small cell lung carcinoma

renal cell carcinoma

triple-receptor negative breast cancer

Therapies

RGX-104

Nivolumab + RGX-104

Age Groups: senior adult

Additional content available in CKB BOOST